Abstract Objective Advancing the understanding of the pathophysiology of eosinophilic oesophagitis (EoE) and other eosinophilic gastrointestinal diseases (EGIDs) has spurred research into targeted biological therapies, while the conclusive therapeutic efficacy of biologics remains uncertain. In this review, we conducted a meta-analysis of all RCTS of biologics in the …

2023年9月15日 · Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction.1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis.2,3 Standard treatments include proton …

2023年1月1日 · Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated. This review focuses on biologics therapy in EoE.

2025年3月27日 · The Consumer’s Guide to Biologics for Eosinophilic Esophagitis Learn everything you need to know about the first FDA-approved treatment for eosinophilic esophagitis.

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg). Serious side effects can occur. Please see Important Safety Information and Prescribing Information and Patient Information on website.